A feasibility study of neoadjuvant Oxaliplatin and S-1 for clinical T3 or T4 gastric cancer

Phase 2

• Conditions: gastric cancer

• Registration Number: JPRN-UMIN000007589
• Lead Sponsor: ational Cancer Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-03-31
• Study Completion: 2016-02-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

Not provided

Exclusion Criteria

1)Enhanced abdominal CT revealed no Bulky lymph node (>=3cmx1 or >=1.5cmx2). 2)No coagulation disorder. 3)Body temperature >=38 centigrade at the time of enrollment. 4) Active bacterial or fungal infection. 5) Interstitial pneumonia, pulmonary fibrosis, or severe emphysema. 6) History of hypersensitivity to L-OHP, Fluorouracil, Tegafur, Gimeracil, Oteracilo Potassium, Dexamethason,or 5-HT3 receptor antagonist. 7) Peripheral motor neuropathy or peripheral sensory neuropathy by any reason. 8) Synchronous or metachronous (within 5 years) malignancies other than carcinoma in situ or mucosal cancer. 9) Under treatment with flucytosine, phenytoin, or warfarin. 10) Women during pregnancy or breast-feeding. 11) Severe mental disease. 12) Under treatment with systemic steroid. 13) Uncontrollable diabetes mellitus or routine administration of insulin. 14) Uncontrollable hypertension. 15) Active gastrointestinal bleeding. 16) Past history of myocardial infarction or unstable angina pectoris within 6 months. 17) HBs antigen positive.

Study & Design

• Study Type: Interventional
• Study Design: Not specified